Here, we analyze mutational profiles of tumor tissue or liquid biopsy samples from real‐world ALK‐positive NSCLC patients who had relapsed on first‐ or second‐line alectinib treatment to elucidate potential resistance mechanisms. This evidence concerns the gene ALK and non-small cell lung carcinoma.